AbbVievsSolventum

ABBV and SOLV stock compared: price, dividend, valuation and results, from SEC filings.

SOLV

Solventum Corporation

$89.08

Value $15.5B

+0.30%
SOLV's page

AbbVie (ABBV) has a market value of $522B and Solventum (SOLV) $15.5B. Over the last year, with dividends, ABBV moved +30.3% and SOLV +20.7%. The P/E is 50.7 for ABBV and 99.1 for SOLV. Dividend yield: ABBV 2.35%, SOLV none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$522B

    SOLV$15.5B

    ABBV is 34 times SOLV

  • Revenue, 12 months

    ABBV$66.0B

    SOLV$8.2B

    ABBV is 8.1 times SOLV

  • Net income, 12 months

    ABBV$10.3B

    SOLV$156M

    ABBV is 66 times SOLV

  • Operating margin

    ABBV32.2%

    SOLV5.6%

    26.6 points apart

  • ROIC

    ABBV25.7%

    SOLV4.2%

    21.5 points apart

  • P/E

    ABBV50.7

    SOLV99.1

    SOLV is 2.0 times ABBV

  • Dividend yield

    ABBV2.4%

    SOLV0.0%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+30.3%

SOLV+20.7%

100120DecFebAprJunAugOct
Returns by period
PeriodABBVWith dividendsSOLVWith dividends
1 year since November 12, 2025+30.3%Price +26.5%+20.7%Price +20.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieSOLVSolventum

Valuation

ABBVSOLV
Valuation
Price$295.03$89.08
Market value$522B$15.5B
Enterprise value (EV)$592B$20.3B
P/E50.799.1
P/E, 5-year median57.0–
P/B–3.2
EV/EBIT27.944.6
Free cash flow yield3.6%–

Results and growth

ABBVSOLV
Results and growth
Revenue, 12 months$66.0B$8.2B
Net income, 12 months$10.3B$156M
Free cash flow, 12 months$18.9B$0
Earnings per share, 12 months$5.81$0.88
Revenue growth, year on year8.6%0.9%
Revenue growth a year, past+5.9%over 5 years+0.8%over 3 years
EPS growth a year, past-2.8%over 5 years+4.5%over 3 years

Margins and returns on capital

ABBVSOLV
Margins and returns on capital
Gross margin73.7%54.8%
Operating margin32.2%5.6%
Net margin15.7%1.9%
ROIC25.7%4.2%
ROE–3.2%

Balance sheet

ABBVSOLV
Balance sheet
Cash$10.8B$451M
Total debt$80.9B$5.3B
Net debt / EBITDA3.25.1
Interest cover7.1×–

Dividends and buybacks

ABBVSOLV
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or SOLV

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Solventum?

By market value, AbbVie ($522B) is about 33.8 times Solventum ($15.5B), at today's prices.

How did ABBV and SOLV stock do over the last 1 years?

Since November 12, 2025, ABBV's price moved +26.5% and SOLV's +20.7%. With dividends: ABBV +30.3% (+30.3% a year), SOLV +20.7% (+20.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or SOLV?

The dividend yield at today's price is 2.35% for AbbVie and none for Solventum. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and SOLV?

At today's price, the P/E is 50.7 for ABBV and 99.1 for SOLV. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, AbbVie or Solventum?

Over the last twelve months, the net margin was 15.7% for AbbVie and 1.9% for Solventum, and the operating margin 32.2% and 5.6%. Revenue was $66.0B and $8.2B.

Which is the better investment, AbbVie or Solventum?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.